Aptose Biosciences (TSE:APS) Reaches New 12-Month High – Here’s What Happened

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) hit a new 52-week high during trading on Thursday . The company traded as high as C$2.40 and last traded at C$2.40, with a volume of 28032 shares trading hands. The stock had previously closed at C$2.14.

Aptose Biosciences Price Performance

The business’s 50 day moving average is C$2.26 and its two-hundred day moving average is C$2.23. The company has a debt-to-equity ratio of -98.74, a quick ratio of 5.41 and a current ratio of 0.55. The firm has a market capitalization of C$6.12 million, a PE ratio of -0.23 and a beta of -1.38.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported C($4.16) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.